Myriad Genetics (MYGN) Receivables - Other (2010 - 2021)

Myriad Genetics has disclosed Receivables - Other across 12 years of filings, most recently posting $2.4 million for Q1 2021.

• In Q1 2021, Receivables - Other fell 4.0% year-over-year to $2.4 million; the TTM figure through Mar 2021 stood at $2.4 million (down 4.0% YoY), while the FY2020 annual figure was $2.0 million, changed N/A from the prior year.
• Receivables - Other rose to $2.4 million in Q1 2021, from $2.0 million in the prior quarter.
• Over the last five years, Receivables - Other for MYGN reached as high as $6.9 million in Q3 2017 and fell as low as $2.0 million in Q3 2020.
• The 5-year median for Receivables - Other is $4.3 million (2018), against an average of $4.1 million.
• Annual changes were most pronounced in 2017 — Receivables - Other surged 72.73% — and 2020, when it tumbled 58.33%.
• A 5-year view of Receivables - Other shows it stood at $6.0 million in 2017, then declined by 1.67% to $5.9 million in 2018, then slumped by 40.68% to $3.5 million in 2019, then sank by 42.86% to $2.0 million in 2020, then increased by 20.0% to $2.4 million in 2021.
• According to Business Quant data, Receivables - Other over the past three periods registered $2.4 million, $2.0 million, and $2.0 million for Q1 2021, Q4 2020, and Q3 2020 respectively.